Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897172 | 1.00 | CHRM5 (0.41) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13025301 | 1.00 | CHRM5 (0.41) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13779618 | 0.82 | CHRM5 (0.39) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16885287 | 0.82 | CHRM5 (0.36) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13064060 | 0.79 | CHRM5 (0.35) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2034622 | 0.79 | CHRM5 (0.40) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL338034 | 0.78 | MAPT (0.36) | CYP1A2MAPTSMN1; SMN2 | |
| SCHEMBL16889979 | 0.77 | CHRM5 (0.38) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9815240 | 0.76 | CYP1A2 (0.47) | CHRM5CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8226932 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105481801-B | Preparation method of pregabalin chiral intermediate | 广东莱佛士制药技术有限公司 | 2021-08-13 | — | — | CN | claimed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| EP-3216863-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2978748-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2017-05-10 | — | — | EP | disclosed |
| CN-105481801-A | Preparation method of pregabalin chiral intermediate | RAFFLES PHARMATECH CO LTD | 2016-04-13 | — | — | CN | disclosed |
| EP-2978748-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | Pfizer Ireland Pharmaceuticals (IE) | 2016-02-03 | — | — | EP | disclosed |
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | PFIZER INC | 2016-01-28 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| WO-2014155291-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PREGABALIN | PFIZER IRELAND PHARMACEUTICALS (IE) | 2014-10-02 | — | — | WO | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20030229054-A1 | Novel amines as pharmaceutical agents | BELLIOTTI THOMAS RICHARD (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| US-6521650-B1 | Novel gamma aminobutyric acids; treatment of epilepsy, faint-ness attacks, hypokinesia, cranial disorders, neurodegenera-tive disorders, depression, anxiety, panic, pain, neuropatho-logical disorders, inflammation and gastrointestinal damage | PFIZER, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1045839-A2 | NOVEL AMINES AS PHARMACEUTICAL AGENTS | Warner-Lambert Company LLC (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999031074-A2 | ((CYCLO)ALKYL SUBSTITUTED)-.GAMMA.-AMINOBUTYRIC ACID DERIVATIVES (=GABA ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024540-A1 | Process and Intermediates for the Preparation of Pregabalin | GABRE, GABRG1, GABRG2 | CHRM5 2119/4885CHRM2 2020/4885CHRM4 1567/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | CHRM5 711/4885CHRM2 265/4885CHRM4 848/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CHRM5 2957/4885CHRM2 2114/4885CHRM4 3127/4885 |
| US-20030229054-A1 | Novel amines as pharmaceutical agents | HTR1B, HTR1A, TPSAB1 | CHRM5 400/4885CHRM2 167/4885CHRM4 487/4885 |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | SCN5A, TRPV1, TRPV5 | CHRM5 192/4885CHRM2 369/4885CHRM4 468/4885 |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | CHRM5 221/4885CHRM2 535/4885CHRM4 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.